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Estrogen accelerates the resolution 
of inflammation in macrophagic 
cells
Alessandro Villa, Nicoletta Rizzi, Elisabetta Vegeto, Paolo Ciana & Adriana Maggi
Although 17β-estradiol (E2) anti-inflammatory activity has been well described, very little is known 
about the effects of this hormone on the resolution phase of the inflammatory process. Here, we 
identified a previously unreported ERα-mediated effect of E2 on the inflammatory machinery. The 
study showed that the activation of the intracellular estrogen receptor shortens the LPS-induced pro-
inflammatory phase and, by influencing the intrinsic and extrinsic programs, triggers the resolution 
of inflammation in RAW 264.7 cells. Through the regulation of the SOCS3 and STAT3 signaling 
pathways, E2 facilitates the progression of the inflammatory process toward the IL10-dependent 
“acquired deactivation” phenotype, which is responsible for tissue remodeling and the restoration of 
homeostatic conditions. The present study may provide an explanation for increased susceptibility to 
chronic inflammatory diseases in women after menopause, and it suggests novel anti-inflammatory 
treatments for such disorders.
The hypothesis that estrogens may play a role in protection against chronic inflammatory diseases stems 
from a large body of clinical and preclinical evidence that has demonstrated that a) the etiology and 
course of chronic inflammatory diseases is influenced by the menstrual cycle and pregnancy1–3; b) a sig-
nificant increase in the incidence of disorders characterized by a strong inflammatory component (e.g., 
osteoporosis, atherosclerosis, diabetes and other metabolic diseases, arthritis and others) is a hallmark 
of the cessation of ovarian functions4; and c) fertile female mammals are less prone than males to these 
diseases5,6. Indeed, circulating estrogens were shown to target cells of monocyte lineage and to mitigate 
several of the aspects of the native immune response. Our prior results in rodent cells showed that mac-
rophages express the classical intracellular receptors α and β (ERα and ERβ )7. In addition, other authors 
demonstrated that also the membrane-bound G-protein-coupled estrogen receptor (GPR30/GPER-1) is 
expressed in murine macrophages8. The ERα -bound estrogen was shown to decrease the synthesis of 
pro-inflammatory compounds9,10, to control mitochondrial mitosis11 and respiratory function12, to induce 
the degradation of damaged proteins through the proteasome13, and to diminish monocyte apoptosis and 
activation of hypoxic genes14. At a molecular level, the hormone-activated ERα was shown to impair 
NF-κ B transcriptional activity by preventing its nuclear translocation in the presence of strong inflam-
matory stimuli (such as lipopolysaccharide, LPS). In this case, the estrogen-dependent prevention of 
NF-κ B activation did not require de novo protein synthesis to modify Iκ Bα degradation, and it occurred 
through a direct interaction between the hormone-activated ERα and phosphatidylinositol 3-kinase10. In 
fact, the intracellular ERα and ERβ , in addition to acting as hormonally regulated transcription factors, 
may also interact with cytoplasmic and nuclear proteins responsible for signal transduction and inter-
fere with their functions15. Recent studies have suggested that, in addition to intracellular receptors, the 
membrane-bound GPR30 receptor may be involved in estrogen anti-inflammatory action by pinpointing 
GPR30-specific agonists that regulate the expression of the cell-surface of Toll-like receptor 4 (TLR4) in 
macrophages8. Monocytes/macrophages are exceptionally plastic cells able to adopt the context-specific 
phenotypes necessary to protect the host from harmful events and to reinstate tissue homeostasis when 
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the inflammatory reaction is over. This is achieved with significant changes in the transcriptome and 
proteome: inflammatory stimuli (derived from microbes, damaged tissues or activated lymphocytes) 
induce macrophages to acquire the pro-inflammatory polarization or M1 consisting of the rapid acti-
vation of NF-κ B and the synthesis and secretion of pro-inflammatory cytokines (e.g., TNFα , IL1β , IL6, 
IL12, and IL23) and chemokines (particularly monocyte chemotactic protein-1, MCP1). These inflam-
matory compounds are responsible for the increased expression of cytotoxic mediators such as inducible 
nitric oxide synthase (iNOS). They are also responsible for increased expression of enzymes relevant for 
the phagocytosis of damaged tissues or microorganisms and for the migration and further recruitment 
of macrophages. This sequelae of events aimed at the rapid and efficient removal of the inflammatory 
stimuli is often the cause of severe damage at the site of inflammation; thus, a well-balanced immune 
response ends with the repair and functional recovery of all damaged tissues. This “resolution phase” is 
carried out by macrophages in concert with the host tissue and other immune cells as lymphocytes and 
occurs by acquiring the conventionally named alternative activation (AA) state or M2a polarization16 in 
which macrophages further prompt the synthesis and secretion of specific anti-inflammatory cytokines 
(mainly IL4 and IL13) by T lymphocytes to finally repress the production of pro-inflammatory cytokines 
(like TNFα , IL12, and IL1β ) and iNOS. Recent studies have shown that macrophages may also activate 
an intrinsic program that converts them to the anti-inflammatory phenotype17. The dampening of the 
inflammatory response is associated with the “acquired deactivation” (AD) or M2c phenotype, char-
acterized by the production of IL10 and TGFβ 16, compounds responsible for the restoration of tissue 
homeostasis through the repair of damaged cells, cell proliferation, restructuring of the connective tissue 
and angiogenesis.
Unexplored so far is whether estrogen anti-inflammatory activity is extended to this second phase 
of the native inflammatory reaction. The aim of our study was to evaluate the extent to which estrogens 
participate in the intrinsic or T-cell-regulated resolution of the macrophage pro-inflammatory polari-
zation stage. The study shows that estrogens interact with the signaling responsible for the onset of the 
resolution phase and are able to shorten the duration of the pro-inflammatory stage and to direct the 
resolution of the inflammation toward the acquired deactivation stage. These findings may be relevant 
particularly for the identification of novel estrogen receptor modulators efficacious in the prevention or 
mitigation of chronic inflammation.
Results
7β-estradiol (E2) opposes interleukin 4 (IL4) induced alternative activation in macrophages. 
IL4 has been described as one of the principal mediators of the transition of macrophages toward the 
resolution stage of inflammation. We therefore investigated the potential involvement of estrogens in the 
response of the mouse leukemic cell line RAW 264.7 of monocyte lineage to IL4. In our experimental 
paradigm, cells were stimulated at time 0 with 20 ng/ml IL4 alone or in the presence of 5 nM E2 and then 
harvested every hour in the following 8 h to measure the content of mRNA encoding arginase 1 (ARG1), 
a well-established marker of the AA. The results in Fig. 1a indicate that the cells responded quite rapidly 
to IL4 stimulation alone. Five hours after treatment with the cytokines, the content of Arg1 mRNA was 
292-fold higher than at time 0 and in the control, untreated cells (not shown). In the cells incubated with 
IL4 and E2, the response was significantly reduced, and at 5 h, the concentration of Arg1 mRNA measured 
was approximately half (58%) with respect to the cells stimulated with IL4 only. Similar results were 
observed with another AA marker, Chi3l3, or Ym1 (Supplementary Fig. S1a). In further experiments, 
harvesting the cells 5 h after treatment showed that E2 inhibition of the response to IL4 was antagonized 
efficiently by co-incubation with the high affinity, specific antagonist of intracellular ERs ICI 182,780 
(Fulvestrant) at a 250 nM concentration. At this concentration ICI 182,780 alone did not affect Arg1 
expression (not shown). The antagonism by ICI 182,780 demonstrated the involvement of ERα or ERβ in 
the E2 interference of IL4-driven expression of the AA polarization marker (Fig. 1b). These results were 
confirmed using another macrophage cell line, J774A.1 (as shown in Supplementary Fig. S1b–e), sug-
gesting that these findings were not restricted to RAW264.7. Measurement of ERα (Esr1) and ERβ (Esr2) 
mRNA showed that the expression of the ERα isoform is predominant in this cell line (Supplementary 
Fig. S2a). The expression of ERα in RAW cells was also assessed by means of immunocytochemistry and 
confocal microscopy, showing that ERα protein accumulates in the nuclear compartment following the 
treatment with 5 nM E2 (Supplementary Fig. S2d). All together, these results led us to conclude that the 
E2 interference of IL4 activity had to be ascribed to the liganded ERα .
STAT 6 is not a direct target of estrogen activity. Several authors showed that the IL4 receptor 
(IL4R) couples with the Signal Transducer and Activator of Transcription 6 (STAT6) and activates the 
transcription of several genes, including the Arg118. To verify whether the E2 effect on the accumulation 
of Arg1 mRNA induced by IL4 was associated with an interference of the E2-ER complex with STAT6 
signaling, we studied the effect of E2 in cells treated with the small molecule selective inhibitor of STAT6, 
AS 1517499. The blockage of STAT6 activity confirmed the major role played by STAT6 in the IL4 
signal transduction because, in the presence of AS 1517499, no significant induction of the Arg1 gene 
expression was observed after IL4 treatment. Nevertheless, AS 1517499 produced a paradox effect in 
cells treated with IL4 and E2 combined; in this case, E2 not only failed to reduce but actually significantly 
increased Arg1 mRNA (119-fold induction) (Fig. 1c). The observation that this latter induction was not 
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antagonized by ICI 182,780 led us to hypothesize the contribution of an ERα -independent pathway 
and to investigate the involvement of an alternative mediator of E2 action, the transmembrane receptor 
Figure 1. IL4 induced production of Arg1 mRNA is regulated by estrogens in Raw 264.7 cells. (a) Time-
course of Arg1 mRNA accumulation after IL4. RAW 264.7 were treated with 20 ng/ml recombinant mouse 
interleukin 4 (IL4, dashed line) alone or with 5 nM 17β -estradiol (IL4+ E2, continuous line). mRNA cell 
content was measured by quantitative RT-PCR and data are expressed as 2−ΔΔCt using the 36B4 transcript 
as an internal reference standard. Dots represent mean ± s.e.m. of three experiments done in triplicate, 
**P < 0.01; ***P < 0.001 by unpaired t-test. (b,c) Arg1 mRNA was measured in cells treated for 5 hours 
with IL4 (20 ng/ml), E2 (5 nM), ICI 182,780 (250 nM), AS1517499 (1 μ g/mL); data were calculated and are 
expressed as in the previous panel. Bars represent the mean ± s.e.m. of 6 experiments done in triplicate. 
*P < 0.05; **P < 0.01; ***P < 0.001 by two-way ANOVA versus control. #P < 0.05; ##P < 0.01; ###P < 0.001 by 
two-way ANOVA versus IL4. §§P < 0.01 by two-way ANOVA.
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GPR30, expressed in RAW 264.7 cells at a high concentration19. Figure 2a shows that the specific agonist 
of GPR30, G1 (5 nM), did not antagonize the induction of Arg1 mRNA by IL4 and the addition to the 
medium of ICI 182,780 did not have any influence on Arg1 mRNA expression. This result was expected 
because the compound is not an antagonist of GPR3020. G1 was per se devoid of any effect on Arg1 basal 
expression (not shown). Conversely, in the presence of AS 1517499, the exposure to IL4 + G1 led to an 
increase of Arg1 mRNA superimposable with the effect of IL4 + E2 (Fig. 2b), and such increase was not 
modulated by ICI 182,780. Moreover, the treatment with the GPR30 specific agonist G15 abolished the 
effect of IL4 + E2 and IL4 + G1 on Arg1 mRNA in the presence of AS 1517499 (Supplementary Fig. S3). 
Taken together, these results suggested that GPR30 was accountable for the STAT6-independent induc-
tion of Arg1 expression previously observed following treatment with E2. This hypothesis was supported 
by the observed effects of the different treatments on the phosphorylation of AKT, a target of PI3K 
involved in the intracellular signaling of GPR301. In the absence of STAT6 inhibitor (Fig. 2c), G1 did not 
Figure 2. Effects of GPR30 stimulation on IL4-induced Arg1 expression. (a,b) Quantitative RT-PCR 
analysis of the abundance of arginase 1 transcripts (Arg1) in RAW 264.7 at 5 h following treatment with IL4 
(20 ng/ml), E2 (5 nM), ICI 182,780 (250 nM), G1 (5 nM), and AS1517499 (1 μ g/mL). Results are expressed 
as 2−ΔΔCt using the 36B4 transcript as an internal reference standard. Bars represent the mean and s.e.m. of 
three separate experiments carried out in triplicate. **P < 0.01 by two-way ANOVA versus IL4 treated cells. 
(c,d) The ratio of the relative quantification of phosphorylated (pAKT ) and total (AKT) intracellular Akt 
proteins measured by means of flow cytometry, as described in the methodology section. Cells were treated 
as in panels a and b. Bars represent the media of the expression measured in 10,000 cells, normalized to 
controls of three separate experiments carried out in triplicate. *P < 0.05; **P < 0.01 by two-way ANOVA 
versus untreated cells. #P < 0.05 by two-way ANOVA versus IL4 only.
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further affect the increased phosphorylation of AKT induced by IL4 (+ 190%); however, in the presence 
of AS 1517499, both E2 and G1 had a significant effect on pAKT accumulation which, compared to IL4 
alone, was highly increased (+ 84%). This effect was not blocked by ICI 182,780 (Fig. 2d). Blockade of 
AKT phosphorylation was observed in the presence of the selective inhibitor of PI3K, LY294002. No 
changes were observed in total AKT content. These results pointed to a complex interplay between IL4 
and E2 in the RAW 264.7 cells, thus suggesting a significant role of the hormone in the induction of the 
resolution phase in this cell line.
IL4 up-regulates the expression of ERa. Next, we investigated the extent to which the expression 
of ERα , ERβ and GPR30 were sensitive to IL4R activation (Supplementary Fig. S2a). QPCR showed that, 
at the Ct selected for the relative measure of the concentration of ERα and GPR30 (Gper1) mRNAs, no 
ERβ amplicon fluorescence was observed and Gper1 mRNA content was 227% higher than ERα mRNA; 
however, ERα mRNA was significantly increased (+ 180%) after IL4 treatment and reached an intra-
cellular concentration comparable to Gper1. Treatment with E2 and ICI 182,780 did not further change 
ERα mRNA content. None of the treatments had a significant effect on Gper1 mRNA. Similarly, when 
we measured ERα protein content (Supplementary Fig. S2b), we observed a significant increase of ERα 
in the presence of IL4 (+ 136%). When E2 and/or ICI 182,780 were tested in combination with IL4, E2 
did not influence its receptor content, which was decreased in the presence of ICI 182,780. This latter 
observation was in line with previous reports on the ability of ICI 182,780 to increase ERα protein 
turnover22. AS 1517499 prevention of ERα up-regulation by IL4 indicated the requirement of STAT6 to 
increase the ERα gene expression (Supplementary Fig. S2c).
These results provided a potential explanation for the opposite effects of E2 on IL4-induced Arg1 
expression: in the presence of a functional STAT6 pathway, ERα content was significantly increased 
by IL4, leading E2 to act predominantly through ERα , which limited the expression of the M2 marker. 
When STAT6 was inhibited, IL4 treatment was not followed by the up-regulation of ERα and E2 pre-
ferred signaling pathways through GPR30, which conceivably had a positive effect on Arg1 transcription.
Mechanism of E2-ERα inhibition of IL4-dependent activation of Arg1 transcription. In sev-
eral cells, including RAW 264.7, prior studies showed that the E2-ERα complex may directly increase 
the expression of the suppressor of cytokine signaling 3 (SOCS3)23 and an ERE motif was found at 
-1493–1489 nt upstream of the Socs3 start site24. SOCS are a family of proteins that are highly relevant for 
the negative feedback that regulates cytokine signal transduction25. In macrophages, IL4 was described 
to decrease Socs3 mRNA and protein concentrations26 in association with the increase of Arg1 expres-
sion27, and in AA/AD-activated macrophages, the expression of SOCS1 is critical for the Arg1-induced 
anti-inflammatory response26. A time course study showed that IL4 did not alter Socs3 expression profile 
which was significantly increased by IL4+ E2 starting from 2 h after exposure to the hormone. The highest 
concentration of Socs3 was reached at 5 h, and remained unchanged up to 8 h (Fig. 3a). Treatment with E2 
alone at 5 h did not cause any change in SOCS3 expression. This is in contrast with prior reports23, likely 
because of the very high concentration of E2 used by Liang et al. (20-fold higher). SOCS3 expression was 
massively induced by IL4+ E2 treatment, as SOCS3 mRNA and protein increased 119-fold and 30-fold, 
respectively (Fig. 3c,d). The effect of the sex hormone was blocked by ICI 182,780 and by the inhibition 
of the STAT6 pathway with the AS 1517499 compound (Fig. 3e,f). We also studied Socs1 mRNA expres-
sion, which was increased after the treatment with IL4 only, while the combined treatments with IL4+ E2, 
IL4+ E2+ ICI, and IL4+ G1 blocked IL4 activity on the gene (Supplementary Fig. S4). Thus, E2, unable 
to modulate SOCS3 in unstimulated RAW 246.7, caused a major production of SOCS3 mRNA and pro-
tein in the presence of IL4. The blockage of such an effect by ICI 182,780 suggested the implication of 
ERα . The observation that STAT6 inhibitor prevented any E2-dependent increase of SOCS3 mRNA and 
protein provided further support for the hypothesis that, in the presence of IL4, E2 preferential signaling 
was via ERα .
We also verified whether other pathways could be involved in E2 inhibition of IL4-induced Arg1 syn-
thesis. Prior studies in tumor cells showed that ERα may cross-couple with the JAK/STAT3 pathways28. 
Indeed, Supplementary Figure S5 shows that, in RAW 264.7 cells, the phosphorylated form of STAT3 
was slightly increased by IL4 (1.4-fold versus controls), possibly because pSTAT3 expression was already 
quite high prior treatments. When IL4 was combined with E2, the pSTAT3 was two-fold higher than in 
controls, and such an effect was antagonized by ICI 182,780. STAT3 is known to regulate the expression 
of genes involved in the resolution phase of inflammation, such as Il10. We therefore tested whether the 
effect of estrogens was associated with an induction of this cytokine. Figure 3b shows a time-dependent 
induction of IL10 only in cells treated with IL4+ E2. Figure  3g,h confirm that E2 was indeed able to 
induce Il10 mRNA when administered in the presence of IL4. The observation that ICI 182,780 and AS 
1517499 blocked the effect of the hormone suggested that its action occurred via the ERα and required 
fully functional IL4R signaling.
All together, these data demonstrated that E2, by modulating the effect of IL4 signaling, had the 
potential to interfere with the resolution phase driven by T lymphocytes.
Studies in wound-healing and in primary macrophage cells have clearly shown that macrophages 
have intrinsic mechanisms for the conversion from the pro-inflammatory to an anti-inflammatory 
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Figure 3. The E2-ERα complex regulates SOCS3 and Il10 synthesis in the presence of IL4 stimulation. 
(a,b) Time-course of Socs3 (panel a) and IL10 (panel b) mRNA accumulation after IL4. RAW 264.7 were 
treated with 20 ng/ml recombinant mouse interleukin 4 (IL4, dashed line) alone or with 5 nM 17β -estradiol 
(IL4+ E2, continuous line). mRNA cell content was measured by quantitative RT-PCR and data are 
expressed as 2−ΔΔCt using the 36B4 transcript as an internal reference standard. Dots represent mean ± s.e.m. 
of three experiments done in triplicate, *P < 0.05; **P < 0.01; ***P < 0.001 by unpaired t-test. (c–h) RAW 
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phenotype17,29; therefore, we next investigated the capacity of E2 to interfere with macrophage intrinsic 
signaling leading to the extinction of the M1 phenotype.
The reduced NF-κB life-span suggests a faster resolution of inflammation in the presence of 
E2 in RAW 264.7 cells. To investigate the evolution of the inflammatory process in time, we generated 
a reporter gene; i.e., the pNF-κ B-Luc2-ires-Egfp (Supplementary Fig. S6a), which is able to gauge the 
state of transcriptional activity of NF-κ B, the master regulator of the expression of most of the cytokines 
responsible for the initial phase of acute inflammation. The reporter promoter was conceived after a 
thorough analysis of the data in the literature and an extended experimental testing as described in the 
methodology section. Briefly, to identify the best NF-κ B responsive element sequences, we analyzed a 
panel of genes involved in innate immunity (Supplementary Table S1) and thus identified two major 
groups of NF-κ B consensus sequences. From these two groups, we selected two sequences for each group 
(called 1A, 1B and 2A, and 2B, Supplementary Table S2) that were particularly enriched in the promoter 
region of genes involved in innate immunity. Studies carried out in transient as well as in stably trans-
fected cells using the NF-κ B reporter demonstrated that activation of the reporter genes was selective, 
as it occurred in the presence of a number of pro-inflammatory stimuli but not the anti-inflammatory 
IL4 (Supplementary Figs S6b–e).
Using this reporter system, we studied the influence of E2 on the course of the inflammatory process in 
RAW 264.7 cells transfected with the NF-κ B reporter and treated with lipopolysaccharide (LPS, 1 μ g/mL) 
to trigger the inflammatory response. The production of the EGFP fluorescence was observed as early 
as 4 h following LPS treatment. From this time point on, the intracellular fluorescence was monitored 
continuously by means of time-lapse microscopy (Fig. 4a). The cells expressed the fluorescent protein for 
22 ± 2 h after LPS; at this time point, the fluorescence disappeared rapidly. At approximately 2 h before 
the disappearance of the fluorescence, we observed membrane blebbing and release of fluorescent ves-
icles in the medium (Supplementary Fig. S7). When the RAW 264.7 cells were treated with LPS for 4 h 
and then with 5 nM E2, the duration of fluorescence expression was significantly shortened: at 8 ± 2 h, 
the cells ceased to express fluorescence after having undergone morphological changes similar to those 
observed in the cells not exposed to E2 (Supplementary Fig. S7). The accelerated loss of EGFP was not 
observed in cells exposed to both E2 and ICI 182,780 or to the GPR30 agonist G1 alone.
These data indicated that the hormone receptor complex was able to reduce the time of NF-κ B tran-
scriptional activity induced in response to a strong inflammatory stimulus, suggesting the ability of the 
hormone to shorten the pro-inflammatory phase, possibly by anticipating the resolution of inflamma-
tion. However, these findings were not in line with the prior described effect of the E2-ERα complex, 
which appeared to limit the ability of IL4 to induce markers of AA polarization. This led us to verify 
whether the termination of EGFP fluorescence in cells treated with E2 was associated with the functional 
changes characteristic of an accelerated loss of the M1 phenotype and conversion to AA/AD. To this aim, 
we investigated the time course of expression of two cytokine hallmarks for either the early phase of 
the pro-inflammatory process (IL1β ) or the initiation of the resolution phase (IL10)30. Figure 4b shows 
that, in RAW 264.7 cells, 2 h after LPS treatment, the content of Il1β mRNA started to accumulate to 
reach its maximal concentration at 7–8 h (4300-fold versus T = 0); from this time on, the content of 
cytokine mRNA slowly decreased and at 24 h after LPS was still significantly higher than in untreated 
cells (585-fold). When cells were co-treated with LPS and E2, the changes in time of Il1β mRNA con-
centrations were quite different, as the max concentration was reached at 5 h after LPS (3,900-fold versus 
T = 0) and the decrease was much steeper than in the LPS-treated cells. By the 12 h, Il1β mRNA content 
was not significantly different than untreated cells. When we focused on the trigger of the resolution 
phase of the inflammatory response, i.e., IL10, we observed that, in cells treated with LPS alone, the Il10 
mRNA started to accumulate at approximately 8 h after the inflammatory insult (60-fold versus T = 0) 
and was 205-fold higher at 12 h than at time 0. When cells were exposed to E2 and LPS together, the 
profile of Il10 mRNA changed significantly as the cells started to accumulate Il10 much earlier than in 
the previous treatment (60-fold versus T = 0 at 3 h), and the highest amount of Il10 mRNA (+ 253-fold 
versus T = 0) was measured at 6–8 h after treatment (Fig. 4c).
Further support for our findings was provided by the observed effects exerted by E2 on phagocytosis, 
another marker of the pro-inflammatory phenotype and a crucial event for the establishment of the 
264.7 cells were treated as described in Fig. 2. (c,e) Quantitative RT-PCR analysis of mRNAs encoding for 
Suppressor of cytokine signaling 3 (socs3); data are expressed as 2−ΔΔCt using the 36B4 transcript as internal 
reference standard. Bars represent the mean and s.e.m. of three separate experiments made in triplicate. 
***P < 0.001 by two-way ANOVA versus untreated cells. (d,f) Representative immunoblots of RAW 264.7 
lysates probed with anti-bodies against SOCS3, and subjected to densitometric analysis. β -actin served as an 
internal loading control. Densitometry values were normalized in controls. The bars represent the mean and 
s.e.m. of the densitometric analysis of three separate experiments. ***P < 0.001 by two-way ANOVA versus 
untreated cells. (g,h) Quantitative RT-PCR analysis of Interleukin 10 mRNAs (Il10); data are expressed as 2−
ΔΔCt using the 36B4 transcript as an internal reference standard. Bars represent the mean and s.e.m. of three 
separate experiments made in triplicate. **P < 0.01 by two-way ANOVA versus untreated cells.
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resolution phase of the inflammatory process31. Figure  4d shows the flow cytometry analysis of RAW 
264.7 cells treated for 6 h with 1 μ g/ml FITC-conjugated LPS in the presence or absence of E2. The engulf-
ment of the fluorescent compound at 6 h was significantly higher (+ 38%) in cells treated with LPS+ E2 
than in controls receiving only the pro-inflammatory stimulus. These data supported the hypothesis of a 
faster onset and evolution of the M1 inflammatory phase in the presence of the sex hormone.
We finally tested how, in this treatment paradigm, the presence of E2 was influencing Socs gene 
expression. As expected, in cells treated with LPS alone, the accumulation of Socs3 mRNA started late 
in the process and was clearly measurable only at 12 h after LPS (590-fold versus T = 0, Fig.  4e). The 
presence of E2 in the medium significantly accelerated the time in which this mRNA started to accumu-
late (360-fold versus T = 0 at 5 h after LPS+ E2). This latter effect was restricted in time, as the cells had 
Figure 4. Estradiol promotes a faster M1-M2 transition in RAW 264.7 cells. (a) Time-lapse fluorescence 
microscopy of RAW264.7 transiently transfected with the NFkB-Luc2-ires-Egfp reporter vector, stimulated 
for 4 h with LPS (1 μ g/ml), and then treated with E2 (5 nM), ICI 182,780 (250 nM), G1 (5 nM), and IL4 
(20 ng/ml). The panel represents time-lapse movies. Frames were captured every 30 min. NF-κ B activity 
is reported by the expression of EGFP (green). Original magnification, × 40. Data representative of six 
independent experiments. (b,c) mRNA expression profile of Interleukin 1β mRNA (Il1β ) and Interleukin 
10 (Il10) measured by quantitative RT-PCR in RAW264.7 treated with 1 μ g/ml LPS (LPS) alone or in the 
presence of 5 nM 17β -estradiol (LPS+ E2). (d) Flow-cytometry histograms of fluorescence associated to 
LPS-FITC engulfed in RAW 264.7 at 6 hours after stimulation with LPS-FITC (LPS, 1 μ g/ml) and co-treated 
with E2 (5 nM). Fluorescence intensity, detected using the FL1 (515 ∼ 545 nm) photodetector, is represented 
in arbitrary units, logarithmic scale. Black line: LPS; gray area: LPS+ E2. Data representative of triplicate 
experiments. (e,f) mRNA expression profile of Suppressor of cytokine signaling 3 (Socs3) and Suppressor 
of cytokine signaling 1 (Socs1) assessed with real-time RT-PCR analysis in RAW 264.7 treated as in panel 
b. (b,c,e,f) Data are expressed as 2−ΔΔCt using the 36B4 transcript as an internal reference standard and 
represent the mean and s.e.m. of triplicate experiments. *P < 0.05; **P < 0.01 by unpaired t-test. Statistical 
significance versus untreated is reported in Supplementary Information.
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ceased to accumulate Socs3 mRNA 12 h after the treatment (Fig. 4e). The maximum expression of Socs3 
mRNA at 6 h was consistent with prior observations on genes directly regulated by the E2-ERα com-
plex32,33. Socs1 mRNA was present in the cells at a concentration much lower than Socs3 mRNA, and its 
production could not be clearly associated to a specific phenotype (Fig. 4f). As expected, no IL4 mRNA 
was synthesized by the macrophagic cell line at any time.
Discussion
The present study provided novel insights on the anti-inflammatory effects of estrogens, potentially rele-
vant to the understanding of the role of estrogen deprivation in the evolution of pathologies characterized 
by a high degree of inflammation. This study, aimed at evaluating the effect of estrogens on the resolution 
of inflammation, indeed showed that the activation of the intracellular estrogen receptor shortened the 
pro-inflammatory phase and influenced the extrinsic and intrinsic programs leading to the resolution of 
the inflammatory phase, favoring the progression of macrophages toward the IL10-dependent AD phase, 
which is responsible for immunomodulation and tissue remodeling.
The mechanisms involved in estrogen-dependent progression of the inflammatory response are multi-
ple: in the absence of stimulation by other immune cells, estrogens preferentially bind the GPR30 recep-
tor and activate the synthesis of Arg1 mRNA through the PI3K-AKT pathway. However, when IL4R is 
stimulated, the intracellular concentration of ERα is increased, and in the presence of E2, this receptor 
activates Socs3 expression, leading to the blockage of IL4R signaling27. At the same time, the E2-ERα 
complex facilitates STAT3 phosphorylation and the activation of the Il10 promoter, as also described 
in cells of different lineage34,35. Interestingly, after the inflammatory insult, E2 appeared to significantly 
accelerate the onset of the AD polarization by hastening IL1β synthesis and anticipating the production 
of IL10 and SOCS3 even in the absence of IL4. Conceivably, in this case, the ERα activity might be 
facilitated by intrinsic factors involved in the response to the inflammatory stimulus (Fig. 5).
The finding that IL4 treatment induces an increase in the expression of ERα (Supplementary Fig. S2) 
is in agreement with previous reports36,37. In particular, the observation of a transient up-regulation of 
ERα mRNA in human macrophages following the treatment with IL4/IL1337 suggested that this IL4 
effect is well conserved in mammals. This phenomenon appeared to be functionally relevant, as the 
increased content of ERα is associated with a decrease in the production of ARG1, the main function 
of which is related to the inhibition of the pro-inflammatory response in the inflammatory process. 
The evidence of a negative effect of E2 on Arg1 expression (Fig. 1a,b) in cells stimulated by IL4 is there-
fore quite surprising, being in apparent contrast with estrogen anti-inflammatory activity. Yet, in the 
inflammation process, the resolution phase is multifaceted38; in addition to the up-regulation of the 
genes, which is a hallmark of the AA phenotype, such as Arg1, and necessary for the diminution of the 
activity of the inflammatory molecules produced, other cytokines (e.g., IL10) are generated to repair 
the damaged tissues in the AD phenotype. Indeed, IL10 was proposed as the marker of the AD pheno-
type39 characterized by pro-healing functions with the release of angiogenetic factors, such as vascular 
endothelial growth factor-A (VEGFA) and transforming growth factor beta (TGFβ ), which are essential 
for tissue repair40.
Our present results indicate that E2, by activating the intracellular ERα , shortens the time spent by 
macrophages in the inflammatory status and facilitates the onset of the AD phenotype. Our findings are 
Figure 5. Representative scheme of the proposed mechanism. 
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in line with and provide mechanistic insights to the reports of an estrogen positive effect on angiogenesis 
and proliferation41–43 or in wound healing of chronic wounds44,45.
Our study may impact the understanding of the causes for the increased incidence of chronic inflam-
matory disorders in women after the cessation of estrogen production by the ovaries. Growing exper-
imental evidence points to a relevant role of macrophage polarization in the progression of several 
pathologies linked to climaterium, the M1 pro-inflammatory state associated with the progression of 
osteoporosis, atherosclerosis and metabolic diseases, including diabetes46–48. Therefore, the ability of E2 
to promote the resolution phase of inflammation may be important for the protective effects exerted by 
the hormone prior to menopause.
The effects of estrogens on macrophage polarization may, however, also have a negative impact on 
health; in fact, in young women, the incidence of pathologies driven by the AA/AD macrophages, such 
as scleroderma49 and asthma50, is significantly higher than in post-menopause51,52. Moreover, in selec-
tive types of cancer, tumor-associated macrophages (TAM) produce IL10 and TGFβ , contributing to 
the general suppression of anti-tumor activities53. It is well known that E2 stimulates proliferation and 
metastatic potential of ERα positive breast cancer cells54, and because tumor progression and resistance 
to chemotherapy are associated with elevated levels of SOCS355 and STAT356, it is tempting to speculate 
that the effects of the estrogen on tumor macrophages may be involved in E2-dependent cancer growth.
The observation that estrogen accelerates the inflammatory process, thus promoting the natural res-
olution of inflammation, suggests an important aspect to be fully exploited for new hormone replace-
ment therapies. Indeed, the current trend in the generation of anti-inflammatory therapies is to create 
drugs able to facilitate the resolution of inflammation57 in order to avoid the collateral effects of classi-
cal anti-inflammatory compounds, which may expose the organism to opportunistic infections58. These 
novel compounds would diminish the extent of chronic inflammation, thus limiting the associated tissue 
damage. Estrogen, via the mechanism here described, would represent an ideal anti-inflammatory treat-
ment for women in post-menopause.
Methods
Reagents. Unless otherwise specified, chemicals were purchased from Merck (Darmstadt, Germany), 
and culture media and additives were obtained from Life Technologies-Invitrogen (Paisley, Scotland, 
United Kingdom). E2, LPS (isotype 0.111:B4), LPS-FITC (isotype 0.111:B4), LY294002, and ICI 182,780 
were obtained from Sigma (Milan, Italy). Recombinant mouse IL4 was obtained from PeproTech 
(London, UK). AS 1517499 was obtained from Axon Medchem BV (Groningen, The Netherlands). G1 
and G15 were obtained by Tocris (Bristol, UK).
Cell cultures. RAW 264.7 and J774A.1 cells were purchased from the American Type Culture 
Collection (Manassas, Va.) and grown in red-phenol free Dulbecco minimal essential medium (DMEM)-
10% DCC serum (DCC; Celbio, EuroClone, Milan, Italy) supplemented with 2 g of sodium carbonate/
liter, 0.11 g of sodium pyruvate/liter, and streptomycin-penicillin (50,000 IU plus 50 mg per liter) in a 
humidified 5% CO2–95% air atmosphere at 37 °C.
Real Time Reverse transcription (RT)-PCR. RNA was extracted from RAW 264.7 cells. All samples 
were resuspended in TRIzol reagent (Invitrogen, Milan, Italy), and RNA was isolated according to the 
manufacturer’s instructions. One microgram of RNA was used for cDNA preparation with Moloney 
murine leukemia virus reverse transcriptase (Promega, Milan, Italy), as previously described7. Control 
reactions without the addition of the enzyme were performed for each sample. A 1:4 cDNA dilution was 
amplified using SYBR green chemistry. The PCR was carried out in triplicate or duplicate on a 96-well 
plate using GoTaq® qPCR Master Mix technology (Promega) according to the manufacturer’s protocol 
using a 7900HT fast real time PCR system (Applied Biosystems, Life Technologies) with the following 
thermal profile: 2 min at 95 °C; 40 cycles, 15 s at 95 °C, 1 min at 60 °C. Gene expression of target genes was 
assessed for Arginase-1 (Arg1; forward primer, 5′ -CAGAAGAATGGAAGAGTCAG-3′ ; reverse primer, 
5′ -CAGATATGCAGGGAGTCACC-3′ ), Esr1 (forward primer, 5′ -GAAGAGTTTGTGTGCCTCAAAT-3′ ; 
reverse primer, 5′ -GTGCCGGATATGGGAAAGGATG-3′ ), Esr2 (forward primer, 5′ -CCACACCATCC 
TCAATCACTAC-3′ ; reverse primer, 5′ -CAGTAACAAGGGCATGGAAC-3′ ), Gper1 (forward primer, 
5′ -CGGCACAGATCAGGACACCC-3′ ; reverse primer, 5′ -TGGGTGCATGGCAGAAATGA -3′ ), Il1β  
(forward primer, 5′ -TGCCACCTTTTGACAGTGATG-3′ ; reverse primer, 5′ -GCTGCGAGATTTGAA 
GCTGG-3′ ), Il10 (forward primer, 5'-GGTTGCCAAGCCTTATCGGA-3′ ; reverse primer, 5′ - ACCTGC 
TCCACTGCCTTGCT-3′ ), Socs3 (forward primer, 5′ - GGAGATTTCGCTTCGGGACT-3′ ; reverse primer, 
5′ - CAGATATGCAGGGAGTCACC -3′ ), Socs1 (forward primer, 5′ - CTCGCTCCTTGGGGTCTGTTG -3′ ; 
reverse primer, 5′ - GCGTGCTACCATCCTACTCGA -3′ ), Il4 (forward primer, 5′ - CGGCATTTTGA 
ACGAGGTCA -3′ ; reverse primer, 5′ - CTCTGTGGTGTTCTTCGTTGC -3′ ).
Data were analyzed using the 2−ΔΔCt method59 using 36b4 as the housekeeping gene (forward primer, 
5′ -GGCGACCTGGAAGTCCAACT-3′ ; reverse primer, 5′ -CCATCAGCACCACGGCCTTC-3′ ).
Western Blotting. Cells were lysed in a buffer for total cellular extracts, containing 5 mM MgCl2, 20 mM 
HEPES (pH 7.9), 420 mM NaCl, 0.1 mM EDTA, 20% glycerol, 0.1% Triton, 5 mM β -mercaptoethanol, 
0.1 mM PMSF, 10 μ g/ml aprotinin, and 1 μ g/ml leupeptin. The lysates were frozen on dry ice for 5 min 
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and then thawed at 37 °C for 5 min for three times. The samples were centrifuged at 13,000 rpm at 4 °C 
for 20 min and the supernatants were collected and stored at − 20 °C. Protein concentration was esti-
mated by a Bradford protein assay using BSA as the standard. Equal amounts of protein (20 μ g) were 
dissolved in Laemmli’s sample buffer, boiled for 5 min, and separated with a SDS-polyacrylamide minigel 
(10% and 7.5% polyacrylamide for Ym1 and CD206 detection, respectively) and then transferred over-
night at 15 mA into 0.45 μ m Hybond-ECL membrane (GE Healthcare, Milan, Italy). Membranes were 
incubated for 1 h with blocking solution containing 5% (w/v) nonfat milk in Tris-buffered saline (TBS) 
and subsequently probed for 1 h at room temperature with rabbit antibodies anti-mouse STAT3 (1:500; 
#12640,Cell Signaling Technologies, USA), pSTAT3 Tyr705 (1:500; #9138, Cell Signaling Technologies, 
USA), STAT6 (1:1000; #9362, Cell Signaling Technologies, USA), pSTAT6 Tyr641 (1:500; #9361, Cell 
Signaling Technologies, USA), ERα (1:500; SC-542, Santa Cruz Biotechnologies, USA), and SOCS3 
(1:1000; #2923, Cell Signaling Technologies, USA) in incubation solution (TBS containing 5% (w/v) non-
fat milk and 0.1% Tween 20. After extensive washing in TBST (TBS + 0.1% Tween 20), blots were incu-
bated with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:2000; PI-1000, Vector Labs, USA) 
in incubation solution, for 1 h at room temperature. After extensive washing in TBST, immunoreactive 
bands were visualized using a chemiluminescence assay detection system according to the manufactur-
er’s instructions (Amersham™ ECL™ Western Blotting Analysis System, GE Healthcare). To ascertain 
that blots were loaded with equal amounts of protein lysates, they were also incubated in the presence 
of the antibody against β -actin protein (1:10,000; Sigma-Aldrich Corp., Milan, Italy). Subsequently, for 
semiquantitative analyses, the densities of the protein bands of STAT3 and pSTAT3 (86 kDa), STAT6 and 
pSTAT6 (110 kDa), ERα (66 kDa), SOCS3 (26 kDa), and β -actin (42 kDa) were measured by densitomet-
ric scanning of the membrane with Gel Doc™ XR Imaging Densitometer (Bio-Rad Lab, Segrate, Italy) 
with a specific software program (Image Studio 4.0, LI-COR Inc.).
PI3-Kinase/Akt activity assay. Modulation of the PI3-Kinase/Akt pathway has been assessed using 
FlowCellect™ PI3K Activation Dual Detection Kit (FCCS025105, Merk-Millipore, USA) a two color flow 
cytometry kit designed to measure the extent of Akt phosphorylation relative to the total Akt expression 
in a given cell population, according to the manufacturer’s protocol. The kit includes two directly conju-
gated antibodies, a phospho-specific Anti-phospho-Akt (Ser473)-Alexa Fluor 488 and an Anti-Akt-Alexa 
Fluor 647 conjugated antibody to measure total levels of Akt. The levels of both the total and phospho-
rylated protein can be measured simultaneously in the same cell, resulting in a normalized and accurate 
measurement of Akt activation after stimulation. Briefly, at the end of the different treatments, cells were 
put on ice, washed three times with PBS, detached by scraping, suspended in 500 μ l PBS. The cells in sus-
pension were pipetted several times to achieve a single cell suspension. Equal volume of ice-cold Fixation 
Buffer has been added to the cell suspension, followed by a 20-minute incubation on ice. Cells were 
spun at 670 × g for 5 minutes in a 4 °C centrifuge, supernatant was aspirated, and the pellet was washed 
twice with the Wash Buffer. Cells were permeabilized by adding 100 μ L of ice-cold Permeabilization 
Buffer and incubated on ice for 20 minutes. Cells have been washed twice with the Wash Buffer and 
resuspended in 90 μ L of assay buffer. For staining, 5 μ L of Anti-phospho-Akt-Alexa Fluor 488 and 5 μ L 
of Anti-Akt-Alexa Fluor 647 were added to each sample. Cells were incubated for one hour on ice 
in the dark, washed twice and resuspended in 200 μ l Assay Buffer. The median fluorescence of 10,000 
cells for each sample was analyzed with a flow cytometry system (BD FACSCalibur, Becton Dickinson 
Biosciences, San Jose, CA, USA).
Assessment of LPS internalization. RAW 264.7 macrophage cells (approximately 2 × 105) were 
stimulated with 1 μ g/ml of FITC-labeled LPS for 1 h and then treated with vehicle or 17β -estradiol (5 nM). 
Internalization of FITC-LPS was monitored at 3 h and 6 h by measuring the mean fluorescence of 10,000 
cells for each sample with a flow cytometry system (BD FACSCalibur, Becton Dickinson Biosciences, San 
Jose, CA, USA); cells stimulated with unlabeled LPS served as autofluorescence reference.
Construction of the pNFκB-Luc2-ires-EGFP plasmid. Each functional cassette of the vector 
NFκ B-Luc2-ires-EGFP was flanked with unique restriction sites to facilitate further manipulations. 
Each element was sequentially cloned, using standard cloning procedures, in the pEGFP-N1 (Clontech 
Laboratories, Inc., 1290 Terra Bella Ave. Mountain View, CA 94043 USA): 1) 641-bp DNA fragment 
encoding IRES element excised from pIRES vector (Clontech Laboratories, Inc., 1290 Terra Bella Ave. 
Mountain View, CA 94043 USA) and cloned into the SacII/AgeI restriction sites; 2) 1642-bp DNA frag-
ment encoding luc2 excised from the pGL4.10 basic vector (Promega Corp., Madison, WI) and cloned 
into the the SalI/SacII restriction sites; 3) 220-bp DNA fragment of NF-κ B responsive elements and 
TATA minimal promoter (Supplementary Fig. S6) excised from the NF-κ B1 vector (see below) and 
cloned into the AseI/SaII. The construct NF-κ B1 was obtained by cloning into the AseI/SalI restriction 
sites of pBluescript II KS+ (Strategene, Agilent Tecnologies, Santa Clara, United States) four selected 
NF-κ B responsive elements, synthetized by Eurofins Genomics, Ebersberg Germany. Then, the 220-bp 
DNA fragment of NF-κ B responsive elements and TATA minimal promoter was excised and cloned 
into the AseI/SaII restriction sites in the pGl2 basic vector (Promega Corp., Madison, WI) in order to 
obtain NF-κ B1. The constructs NF-κ B1.2, NF-κ B1.3, NF-κ B1.4, NF-κ B1.5, NF-κ B1.6 and NF-κ B1.7 
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were derived from NF-κ B1 by sequential partial digestion in order to obtain the corresponding NF-κ B 
responsive elements arrangements.
Transient Transfection. RAW 264.7 cells were seeded into 24-well plates (approximately 2 × 105 cells 
per well) and cultured overnight. Transfections were carried out using the X-tremeGENE HP DNA trans-
fection reagent (Roche), following the manufacturer’s instructions. Two μ g of pNF-κ B-Luc2-ires-Egfp 
were added into 200 μ l red-phenol free DMEM (Celbio, EuroClone, Milan, Italy) before mixing with 
6 μ l of X-tremeGENE HP DNA transfection reagent. The plasmid DNA/X-tremeGENE HP mixture was 
incubated at room temperature for 25 min and then added into each well of the 24-well plates. Cells were 
incubated for 48 hours in a humidified 5% CO2-95% air atmosphere at 37 °C before treatments.
Time Lapse fluorescence microscopy. Culture medium was removed and substituted with 1 ml 
of fresh medium. Cells were treated with LPS (1 μ g/ml), incubated for 4 h in a humidified 5% CO2-
95% air atmosphere at 37 °C, and then co-treated with vehicle, 17β -estradiol (5 nM), G1 (5 nM), ICI 
182,780 (250 nM), or IL4 (20 ng/mL). Time-lapse images were recorded at 40x magnification in phase 
contrast and in fluorescence using a GFP filter (Excitation wavelength, 457–487 nm; emission wave-
length, 502–538 nm) using a Zeiss Axiovert 200 M microscope (Carl Zeiss), beginning right after the 
co-treatment and ending after 24 h. 24-well plates were inserted in a cell cultivation system consisting 
of a heated microscope stage, incubator box, atmosphere controlling device (CTI controller 3700, Carl 
Zeiss) equipped with a humidifier, and a temperature controlling device (Tempcontrol 37–2 digital, Carl 
Zeiss). The CTI controller 3700 supplied the cultivation chamber with a heated mixture of CO2/air. The 
CO2 concentration and the temperature were continuously monitored and regulated by a digital feedback 
control algorithm, enabling a regulated dispersion of CO2 into the air stream and steady heating. Images 
were acquired every 30 min at each of the 24 positions with an AxioCam digital camera (Carl Zeiss) 
controlled by the AxioVision 4.2 software (Carl Zeiss).
Luciferase enzymatic assay. Supernatants containing luciferase were collected and total protein 
concentration was determined with a Bradford assay. Luciferase enzymatic activity in tissue extracts was 
then assayed with a luciferase assay buffer (470 μ m luciferine, 20 mm Tricine, 0.1 mm EDTA, 1.07 mm 
(MgCO3)4·Mg(OH)2 × 5H2O; 2.67 mm MgSO4 × 7H2O in H2O, pH 7.8, with 33.3 mm DTT and 530 μ m 
ATP). The light intensity was measured with a luminometer.
Statistical analysis. Unless otherwise stated, statistical significance was assessed by an unpaired 
t-test or two-way ANOVA using Bonferroni’s multiple comparison post hoc tests that were performed 
with GraphPad Prism 5 (GraphPad Software).
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